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Abstract 
Introduction: Renal cell carcinoma (RCC) accounts for 2-3% of all solid tumors. Expression of the 
receptor for the Vascular Endothelial Growth Factor (VEGF) is one of the most common features of 
RCC.  
 
Areas Covered: Lenvatinib is a novel multi-kinase inhibitor that has been studied in several solid 
tumors. It has shown promising results in the treatment of RCC, especially when combined with 
everolimus, In this review, we summarize the available data of lenvatinib for the treatment of 
advanced/metastatic renal cell carcinoma.  
 
Expert Opinion: Lenvatinib in combination with everolimus has provided encouraging results in 
both clinical and laboratory investigations showing that blocking angiogenesis and the mTOR 
signalling pathway could be a remarkable approach for treating RCC. As an additive to this type of 
approach it would be interesting in future clinical settings testing also the combination of lenvatinib 
and everolimus with immune-therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 Introduction 
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Kidney cancer is the eight most common cancer-related cause of death in the world, with just in the 
USA an estimated 63,340 new diagnoses and 14,970 deaths in 20181. The incidence of the disease 
is expected to increase by about 2% this year compared to last year1,2. 
Renal cell carcinoma (RCC) originates in the renal cortex and it is responsible for approximately 
90% of all primary renal neoplasms, with a prevalence twice as high in men compared to women. 
Although different drugs are currently available for RCC, the prognosis of the metastatic stage of 
disease still remains poor3–5.  
While conventional chemotherapy for RCC reported relatively poor outcomes, some innovative and 
biological drugs have been implemented for the treatment of RCC patients in the past ten years. 
Such treatments, including small tyrosine kinase inhibitors of the Vascular Endotelial Growth 
Factor Receptor (VEGFR) mTOR inhibitors and checkpoint inhibitors. In particular, after sunitinib, 
the Food and drug administration (FDA) approved other antiangiogenic drugs such as sorafenib, 
pazopanib, axitinib, and bevacizumab. Furthermore, the FDA approved mTOR inhibitors 
temsirolimus and everolimus and recently, the only two agents able to improve survival, 
cabozantinib and nivolumab5. 
In this context, lenvatinib, a novel tyrosine kinase inhibitor selectively targeting VEGFR-1, 
VEGFR-2, VEGFR-3, fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3 and FGFR4), 
platelet-derived growth factor receptor (PDGFRα), proto-oncogenes RET and c-KIT6-8. 
Motzer RJ et al. showed increased Progression Free Survival (PFS) and Overall Survival (OS) with 
the combination of lenvatinib plus everolimus in comparison to everolimus alone in a multi-centred 
randomized-to-control phase II study of RCC9. The aim of this mini-review is to summarize the first 
preliminary and clinically available data on lenvatinib in advanced/metastatic RCC. Finally, future 
directions will be discussed. 
 
 
2. The molecular bases of tumor angiogenesis 
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It was not until relatively recent times that sporadic and hereditary mutations in the Von-Hippel-
Lindau (VHL) gene were proven responsible for the development of RCC. The VHL gene was 
found on the human chromosome 3p25.5 for the first time in 199310 as a tumor suppressor gene.  
Other than being implicated in the inherited von Hippel-Lindau disease, mutations of this gene are 
also found implicated in sporadic RCC. Mutations of the VHL gene have been associated with the 
majority of cases of sporadic RCC11. After these first discoveries, the pathway was considered as a 
potential candidate for targeted therapy of this disease. One of the most well-known targets of VHL 
gene is the hypoxia-inducible factor α (HIF-α), a transcription factor involved in the regulation of 
various angiogenic factors. In fact, in the absence of oxygen, HIF-α interacts with its heterodimer 
hypoxia-inducible β (HIF-β) to form a complex that leads to the transcription of hypoxia-inducible 
genes such as vascular endothelial growth factor (VEGF), platelet-derived growth factor β (PDGF-
β), transforming growth factor α (TGF-α) and erythropoietin (EPO). In the presence of oxygen, 
however, the pVHL binds and hydroxylases two proline residues of HIF-α leading to its 
ubiquitination and subsequent degradation by proteasomes10. The presence of VHL gene mutations 
leads to inactivation of this oxygen-dependent degradation of HIF-α with an up-regulation of 
angiogenic factors. 
In physiological conditions, and especially during early stages of life, angiogenesis is an important 
process by which new blood vessels are formed in order to deliver required oxygen and nutrients to 
peripheral tissues, maintaining the required levels of perfusion. Considered nowadays as a universal 
cancer hallmark, neo-angiogenesis in the context of a tumour provides new blood vessels that will 
ultimately result in enhanced tumor growth and increased metastatic potential. One of the most 
common features of cancer neo-angiogenesis is that it is highly regulated. It is mainly based on the 
interactions between tissue soluble VEGFs ligands and VEGFRs. These interactions work perfectly 
in healthy conditions, while they become deleterious during tumourigenesis and cancer progression. 
Sub-variants of VEGF molecules in humans are VEGF-A, VEGF-B, VEGF-C, VEGF-D and 
placental growth factor (PlGF)12,13. The VEGF receptor family consists of three molecular subtypes 
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(VEGFR-1, VEGFR-2 and VEGFR-3), which are type-II transmembrane tyrosine kinase (TK) 
proteins12. Among these receptor subtypes, the main one associated with the pathological formation 
of blood vessels in the context of solid tumors is VEGR-2 (Figure 1). 
VEGFR-2 is usually expressed on the surface of vascular endothelial cells and circulating bone 
marrow-derived endothelial progenitor cells13. Upon binding of VEGF molecules to VEGFR-2, the 
receptor dimerizes and auto-phosphorylates at the carboxyl-terminal TK domain leading to 
activation of the signaling transduction pathway downstream. Consequently, various specific 
molecular pathways are activated at the same time (Figure 1): the PLCγ/PKC/MAPK pathway, 
related to endothelial cells migration; the PI3K/AKT/mTOR pathway, whose activation leads to 
increased survival of endothelial cells and increased vascular permeability; the Raf/MEK/Erk 
pathway, which promotes endothelial cells proliferation14,15. The VEGFR-2 has a significantly more 
robust kinase activity than VEGFR-1 even if the binding between VEGF-A and VEGFR-2 (KDR 
Flk-1 in mice) occurs with an affinity one order lower than that of VEGFR-1 (Flt-1 in mice) (Kd= 
1-10 pM)14. The activation of the VEGFR-2 kinase activity results in a dramatic increase of blood 
vessels’ formation, translating in an increased micro-vessel density and enhanced proliferation rate 
of vascular endothelial cells13. A larger study, enrolling 1091 RCC patients, showed that 79.6% of 
patients were positive for VEGF, 62.4% were positive for VEGFR2, 45% were positive for PDGF-
B and 42.5% were positive for PDGFR-β16. On the basis of these data, VEGFR-2 is considered a 
key player in the process of tumor neo-angiogenesis in solid tumors and RCC. As a consequence, 
VEGFR-2 represents an attractive target for the development of novel anti-cancer therapies. 
Sub-variants of fibroblast growth factor (FGF) molecules in humans are FGF1-10. The receptor 
family consists of four molecular subtypes (FGR-1, FGR-2, FGR-3 and FGR-4), which are highly 
conserved TK receptors. There are differences among subtypes in their ligand affinities and 
distribution across tissues17-19. Among the FGFR receptor-family, the most commonly amplified 
was the FGFR1, affected in 3.5% of the tumours20. Moreover, a study looking at 100 primary 
tumors and 40 metastatic lymph nodes obtained from 140 untreated RCC, showed that FGFR1 and 
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FGFR2 were highly expressed in RCC by immunohistochemistry. Expression of FGFR1 was 
observed in 98% (98/100) of primary tumorous and in 82.5% (33/40) of lymph node metastases. 
FGFR2 was expressed in 4% (4/100) of primary tumors and 5% (2/40) of lymph node metastases. 
In normal kidneys FGFR1 expression was significantly lower (p=0.0001) than in RCC21. 
There is strong evidence pointing out that fibroblast growth factor-2 (FGF2) has an important role 
in angiogenesis besides the VEGF. As a matter of fact FGF2 is a potent regulator of many cellular 
functions, such as proliferation, migration, survival, adhesion, motility, apoptosis and physiological 
functions like wound healing, tumorigenesis, angiogenesis, or blood vessel remodelling or 
embryonic growth22-24 . 
Other key studied pro-angiogenic factors include TGF-β Smad, RAS/RAF1/MEK1-2/ERK1-2, 
DAG/PKC as well as the PI3K/AKT/mTOR and other hypoxia-related genes25,26. These are all 
factors that increase tumour cell proliferation, growth, survival and angiogenesis. 
Therefore, since in RCC there is a high expression of VEGF, VEGFR2, FGFR1, PDGF-B and 
PDGFR-β, patients could potentially benefit from a drug that could inhibit multiple tyrosine kinases 
 
3. Lenvatinib: preclinical  and  phase I data 
Lenvatinib (4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-
carboxamide), is an oral multi-kinase inhibitor capable of selectively inhibit VEGFR1-3 
(WO02/32872) and other pro-oncogenic and pro-angiogenic receptor tyrosine kinases, such as 
FGFR1-4, PDGFR, RET (US9006256) and c-KIT (US7612208B2)6-8. 
Both in vitro and in vivo analyses were able to prove that lenvatinib plus everolimus were able to 
enhance anti-tumor activity. Matsuki et al using 3 human RCC xenograft mouse models (A-498, 
Caki-1 and Caki-2) proved that the combination of lenvatinib and everolimus was able to inhibit to 
a greater extent the tumor growth in all the three cell lines compared to each single monotherapy, 
and even tumor regression was observed in two of the xenografted models, A-498 and Caki-1. In 
these latter two cell lines, the authors pursued an angiogenesis investigation. The A-498 xenografts 
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received lenvatinib plus everolimus and the effect of the combination was equivalent to that of 
lenvatinib monotherapy, suggesting that angiogenesis was primarily suppressed by lenvatinib. A 
gene array expression by the authors further confirmed the results, showing that angiogenesis-
related genes were down-modulated mainly by the lenvatinib therapy. Moreover, the anti-
angiogenesis in A-498 xenografts were associated with tissue hypoxia. In Caki-1 cell line 
xenografted model, tumor microvessel density was significantly reduced by either lenvatinib or 
everolimus monotherapy. In the 2 cell lines that had tumor regression after receiving the 
combinatory therapy, the authors pursued also an antiproliferative activity analysis27,28. Further 
evidence by the group proved that lenvatinib with everolimus had a synergistic inhibition of both 
VEGF and FGF induced proliferation and tube formation in HUVEC cells in vitro. In vivo mice 
results proved that lenvatinib monotherapy at 7.5 mg/kg and everolimus monotherapy at 15 mg/kg 
significantly inhibited tumor growth vs. controls of both mice models, and that the combination of 
lenvatinib (7.5 mg/kg) with everolimus (15 mg/kg) proved to have a significantly higher anti-tumor 
activity vs. each of the monotherapies used at the same or even higher doses28.   
The first clinical evidence showing antitumor activity for lenvatinib in RCC comes from a dose-
escalating Phase I study (NCT00121719). This trial was designed in such a way that RCC patients 
received lenvatinib with the defined purpose of determining the maximum tolerated dose (MTD), 
which was at 25 mg per day. Partial responses (PRs) were observed in 9% of all the patients and 
stable disease in 46%. The median PFS in RCC was of 477 days (95% CI; 279-559), which was 
higher than what has been observed of the conventional RCC treatments. Major adverse events 
were hypertension (40%; grade ≥ 3: 11%), diarrhoea (45%), proteinuria (26%; grade ≥ 3; 7%), 
nausea (37%), stomatitis (32%) and vomiting (23%)29. 
Subsequently, since everolimus has been already FDA approved for the treatment of RCC in 2015, 
its combination with lenvatinib represented a valid, rational approach to be tested for the treatment 
of the disease. The first evidence proving the feasibility of combining lenvatinib plus everolimus in 
RCC comes from a Phase Ib trial. This trial was made of 20 patients with advanced RCC and it was 
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designed with 2 cohorts: in cohort 1, 12mg of lenvatinib and 5 mg of everolimus were administered 
daily; in cohort 2, subsequently 12 mg of lenvatinib and 5 mg of everolimus were given daily. This 
trial  was designed to determine MTD, which was at 18 mg lenvatinib/5-mg everolimus. The 
progression rate across patients was of 30% (95% CI: 11.9%-54.3%). About 20% (95% CI 5.7%-
43.7%) of patients had stable disease after 83 weeks. The median PFS was of 330 days (95% CI: 
157-446; approximately of 10.9 months). The 6- and 12-months PFS were of 72.1% (95% CI 48.8-
95.4%) and 49.5% (95% CI 22.7-76.2 %), respectively30. As to safety concerns, in this phase Ib trial 
the most frequent adverse events for the combination of the two drugs arm were fatigue (60%; 
grade ≥3: 10%), inflammation of the mucosa (50%), diarrhea (40%; grade ≥3: 10%), nausea (40%), 
proteinuria (40%; grade ≥ 3: 15%), vomiting (40%; grade ≥3: 5%) and hypertension (40%). 
 
3.1 Phase II and future III trials 
Motzer and colleagues conducted a randomized, phase 2, multi-center clinical trial   
(NCT01136733) with .purpose of testing whether the combination of lenvatinib plus everolimus 
was superior in terms of PFS compared to the single agents. For this purpose the authors of the trial 
designed a randomized, phase 2, open-label, multicenter study at 37 centers in five different 
countries (UK, Spain, Poland, Czech Republic and the USA). The treatment was administered for 
28 day continuous cycles giving to patients lenvatinib (18mg/day) as one 10mg capsule and two 
4mg capsules plus everolimus (5 mg/day) as one 5mg tablet. Patients in the single agent arm with 
lenvatinib (24 mg/day) were given as two 10 mg capsules and one 4 mg capsule. Patients in the 
single agent arm with everolimus (10 mg/day) were given two 5mg tablets. From a total of 153 
RCC cases, 50 patients received everolimus as a single drug, 51 received lenvatinib with 
everolimus, 50 patients received lenvatinib as a single drug. PFS was the primary end-point of the 
study. The median PFS was higher for the combination of lenvatinib plus everolimus, (PFS of 14.6 
months [95% CI, 5.9-20.1]) compared to the arm of patients treated with everolimus alone (PFS of 
5.5 months [3.5-7.1]) (hazard ratio [HR] 0.40, 95% CI 0.24-0.68; p=0.0005). On the other hand, a 
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not statistically significant difference was observed for the lenvatinib plus everolimus arm 
compared to the lenvatinib as single-agent arm (PFS of 7.4 months) (95% CI 5.6-10.2]; HR 0.66, 
95% CI 0.30-1.10; p=0.12). The single-agent lenvatinib arm showed higher PFS compared to 
single-agent everolimus arm (HR 0.61, 95% CI 0.38-0.98; p=0.048)9. 
The secondary endpoint was Overall Response Rate (ORR), which  showed to be significantly 
higher using the combination of lenvatinib plus everolimus in comparison to single-agent 
everolimus (43% vs. 6%, respectively; PR 7.2; 95% CI 2.3-22.5; p<0.0001), but not when 
compared to single agent lenvatinib (43% vs. 27%, respectively; PR 1.6; 95% CI 0.9-2.8; p=0.10). 
Additionally, the ORR difference between single-agent lenvatinib and single agent everolimus was 
also significantly higher (27% vs. 6%, respectively; PR 4.5; 95% CI 1.4-14.7; p=0.0067)9.  
Authors performed also a post-hoc analysis to prove the robustness of the statistical analysis31. They 
used a blinded, independent radiological review (IRR) to assess the efficacy of their results. The 
primary end point PFS was assessed by IRR in the intention to treat population. The IRR also 
assessed OS and best objective responses. The primary endpoint was always PFS. In the 
combination arm PFS was assessed by IRR was 12.8 months (95% CI 7.4-77.5); in the lenvatinib-
alone arm PFS was 9.0 months (95% CI 5.6-10.2) and in the everolimus-alone arm it was 5.6 
months (95% CI 3.6-9.3). PFS was significantly higher in the combination group compared to the 
everolimus single-agent group (HR 0.45 [95% CI 0.27-0.79]; p=0.0029). Moreover, the post-hoc 
analysis proved that the OS was of 25.5 months in the lenvatinib plus everolimus arm; 19.7 months 
the lenvatinib single-agent arm and 15.4 months the everolimus single-agent arm. The comparison 
between lenvatinib plus everolimus and everolimus alone was statistically significant (HR: 0.51, 
95% CI 0.30-0.88; p=0.024). While the comparison between single-agent lenvatinib and everolimus 
single-agent was not significant (HR: 0.68; 95% CI 0.41-1.14; p=0.12). Finally, no statistically 
significant correlation was observed between the combination of lenvatinib plus everolimus and 
lenvatinib used as single-agent (HR: 0.75, 95% CI 0.43-1.30; p=0.32). Therefore, the combination 
of everolimus with lenvatinib compared to the everolimus single-agent was the unique to show a 
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significant OS improvement. As the authors suggested, the differences between this post-hoc 
analysis and their initial studies was potentially due to the reduced statistical power resulting from 
the fewer IRR-assessed patients at progression events of the post-hoc analysis31. As to safety 
concerns, the high grade adverse events for the combination of the two drugs arm were d to diarrhea 
(85%; grade ≥3: 20%), hypertension (41%; grade ≥3: 14%) and fatigue (59%; grade≥3: 14%) with 
the 71% of patients that required a dose reduction due to adverse events and about one quarter of 
patients that discontinued the treatment. Interestingly, grade 3–4 adverse events occurred in 71% of 
patients receiving lenvatinib+everolimus and in 79% for single-agent lenvatinib. However, no data 
on quality of life is available because it was not investigated12. However, based on the positive 
results of the phase II clinical trial, the combination between lenvatinib and everolimus received 
FDA approval for the treatment of advanced renal cell carcinoma following one prior anti-
angiogenic therapy. 
 
To date, there are several ongoing clinical trials testing lenvatinib as either first or second line 
therapy in the treatment of RCC (table 1).  A Phase II, randomized, open-label and multicenter 
clinical trial is looking at lenvatinib in combination with everolimus in the treatment of non clear 
cell RCC who have not received any therapy for advanced disease. Participants must have one of 
the following subtypes of nccRCC: papillary, chromophobe, collecting duct carcinoma, renal 
medullary carcinoma or unclassified (NCT02915783). Another Phase II open label pilot study, aims 
at primarily measuring ORR in patients treated with the combination of lenvatinib plus everolimus 
before cytoreductive nephrectomy (NCT03324373). The combination of everolimus and lenvatinib 
has been also tested in a phase II, randomized, with parallel assignment and triple masking 
(participant, investigator and outcome assessor) clinical trial aiming to primarily investigate ORR 
and Treatment Emerged Adverse Events in RCC patients, who previously received one anti-VEGF 
treatment. The study consists of two arms giving different concentrations of the two drugs: for arm 
A patients received 18mg of lenvatinib and 5mg of everolimus, while for arm B patients received 14 
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mg of lenvatinib plus 5mg of everolimus (NCT03173560). Finally, a randomized, multi-centered, 
parallel assignment, open-label, phase III clinical trial made of 735 patients has been designed in 
order to test primarily PFS of first line lenvatinib in combination with everolimus (Arm A), or 
pembrolizumab (Arm B) compared to sunitinib (Arm C) in patients with mRCC. The study also 
aims to investigate OS and ORR as secondary outcomes (NCT02811861).This trial has been made 
to compare the efficacy and safety of the combination of these three arms as first-line treatment 
through the measurement of PFS. As major secondary outcome OS, ORR, AEs will be evaluated. 
 
4. Expert Opinion 
Lenvatinib in combination with everolimus has provided encouraging results in both clinical and 
laboratory investigations showing that blocking angiogenesis and the mTOR signalling pathway 
could be a remarkable approach for treating advanced RCC. Interestingly more clinical trials, 
including a randomized phase III study, have been directed to investigate this combinatorial 
treatment in the first line setting. Moreover since RCC is a heterogeneous tumour, it would be 
interesting to test biomarkers of effectiveness to the treatment with lenvatinib, such as levels of 
FGFs, FGFR1/2, VEGFs, VEGFR2, PDGF-B and PDFGR-β. Furthermore, it would be also 
interesting to test targets of the PI3K pathway for effectiveness to the treatment with everolimus. As 
an additive to this type of approach future clinical trials will test also the combination of lenvatinib 
and everolimus with immune-therapy. In fact, preclinical data in vitro have shown that the 
combination of lenvatinib, used at the therapeutic dose of 0.12 mg, with 104 rat uterine cancer 
adenocarcinoma (RuCa)-sensitized lymphocytes administered continuously in 7-days cycles, the 
antitumor effect was higher compared to single agents treatments prolonging survival of mice with 
RCC. Moreover in three cell lines (ACHN, 786-0 and RuCa cells) apoptosis significantly increased 
when sensitized lymphocytes were added to lenvatinib compared to control (p<0.01)32. In addition, 
mouse models showed that mice inoculated with liver cancer, melanoma or colon cancer cell lines 
treated with a combination of lenvatinib (10 mg/kg, once in a day) and anti-mouse PD1 antibody 
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(500g/mouse, twice in a week) had a substantial inhibition on tumour growth when compared to 
individual treatments. Moreover, a greater number of mice demonstrated complete response of 
tumour in the combination therapy group compared to single treatments32,33. Therefore, the 
combination of agents targeting VEGF and cellular immunotherapy-mediated pathways may block 
at the same time two critical signaling pathways activated in RCC, overcoming thereby some partial 
mechanisms crucial for the development of drug resistance in single agent therapy. In an era where 
immune-therapy is constantly progressing at a high pace, with always newer and more powerful 
molecules, the combination of lenvatinib with everolimus to some immune-modulation therapy in 
future randomized clinical trials could be also an interesting approach deserving some clinical 
validation. 
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Figure 1. VEGFR-2 and VEGF molecular pathways; FGFRs and molecular pathways; PDGFRs 
and molecular pathways; RET and molecular pathway; c-KIT and molecular pathway. 
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Table 1: Selected ongoing trials with Lenvatinib in renal cell carcinoma. 
 
Clinical trial 
identifier 
Study De-
sign 
Intervention/s Setting Primary 
endpoint 
Phase Status 
NCT02811861 735 patients, 
Randomized,  
Open label  
Lenvatinib + evero-
limus (Arm A: 18mg 
daily for lenvatinib 
and 5mg daily for 
everolimus) or Len-
vatinib + pembroli-
zumab (Arm B: 
20mg daily for len-
vatinib plus 200mg 
pembrolizumab dai-
ly) vs Sunitinib (Arm 
C: 50mg daily) 
First line PFS 3 Recruiting 
NCT03173560 20 partici-
pants, 
Randomized, 
Parallel as-
signment, 
Triple mask-
ing (Partici-
pant, Inves-
tigator, Out-
comes As-
sessor)  
Lenvatinib + evero-
limus (Arm A: 18mg 
daily for lenvatinib 
plus 5mg for evero-
limus; Arm B: 18mg 
daily for lenvatinib 
and 5mg daily for 
everolimus) 
Second 
line 
ORR, 
TEAEs 
2 Recruiting 
NCT03324373 13 partici-
pants, Single 
group as-
signment, 
Open label  
Lenvatinib + evero-
limus (18mg daily for 
lenvatinib plus 5mg 
daily for everolimus) 
First line ORR 2 Not yet 
recruiting 
NCT02915783 31 partici-
pants, Single 
group as-
signment, 
Open label  
Lenvatinib + evero-
limus (18 mg daily 
for lenvatinib plus 
5mg daily for evero-
limus) 
First line ORR 2 Recruiting 
Abbreviations: Progression Free Survival, PFS; Overall Response Rate, ORR; Dose Limiting Tox-
icity, DLT; Maximum Tolerated Dose, MTD; Recommended Phase 2 dose. 
 
 
